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Introduction: Early diffuse systemic sclerosis (dcSSc) is a multisystem disease 
characterized by rapid changes of skin and internal organs. Our objective was to 
develop a composite response index in dcSSc for use in randomized controlled 
trials (RCT). 
Methods: We followed well-established consensus and data-driven approaches 
and subsequently developed paper patient profiles (n =150) using 2 cohorts of 
dcSSc. Scleroderma experts were invited to rate 20 patient profiles each and 
assess if each patient had improved or not over a period of 1 year. Using profiles 
where consensus was reached, we fit logistic regression models where the 
binary outcome referred to whether patient was improved or not, and the change 
in the core items from baseline to follow-up were entered as covariates. For each 
model, sensitivity and specificity were computed. We tested the final index in a 
previously completed RCT. 
Results: Sixteen of 31 core variables were chosen to be included as part of the 
patient profiles after consensus meeting and review of test characteristics of 
patient-level data. Forty experts rated profiles and the logistic regression model 
(including changes in the modified Rodnan skin score, forced vital capacity % 
predicted, patient and physician global assessments, and HAQ-DI over 1 year) 
had sensitivity of 0.982 (95%CI 0.98-0.983) and specificity of 0.931 (95%CI 
0.929-0.932) and highest face validity. In addition, consensus was achieved for 
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subjects deemed as non-improved based on a significant decline in renal or 
cardiopulmonary involvement. The index was able to differentiate methotrexate 
from placebo in a RCT (p< 0.05). 
Conclusion: We have developed a composite response index applicable to 
study of dcSSc.  
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Systemic sclerosis (Scleroderma, SSc) is one of the most fatal rheumatic 
diseases[1], and is associated with substantial morbidity and many detrimental 
effects on health-related quality of life[2]. Recent years have seen progress in the 
development and validation of outcome measures and refinement of trial 
methodology in SSc [3-6]. This is paralleled by an increased understanding of the 
pathogenesis of SSc [7] and development of targeted therapies [8]. Modified 
Rodnan Skin Score, a measure of skin thickness [5], has been used as the 
primary outcome measure in clinical trials of diffuse cutaneous SSc (dcSSc). 
However, the complexity and heterogeneity of the disease mandate a composite 
response measure that will capture different organ involvements and patient-
reported outcomes. Validated combined response indices are more likely to be 
responsive to change than individual measures [9-11], will facilitate drug 
development and improve assessment of efficacy of therapeutic intervention.   
 
A useful composite index in dcSSc would provide a measure that may improve 
the ability to measure efficacy facilitate comparison of responses across trials 
and provide an improved assessment of efficacy of therapeutic agents. 
Regulatory and funding agencies would then have greater confidence in 
proposals for interventions, and medical professionals and patients could obtain 
new evidence on the efficacy of various interventions in the short and long term. 
This would significantly improve the potential to manage dcSSc. In addition, a 
composite index would facilitate the standardization, conduct, reporting, and 
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interpretation of clinical trials and could also aid in comparing therapies from 
different trials.  
Therefore, our objective was to develop a composite response index in dcSSc 
(CRISS) for use in clinical trials. 
 
Patients and Methods: 
 
This iterative process included well-accepted expert consensus [12] and data 
driven approaches (Figure 1).  
Consensus meeting: Members of the Scleroderma Clinical Trials Consortium 
(SCTC) participated in a Delphi exercise followed by face-to-face nominal group 
technique (NGT) and this approach has been published elsewhere [4]. Domains 
and instruments were selected for subsequent data collection. 
Data-driven exercise:  
A. Longitudinal observational cohort: Due to a lack of positive trials in dcSSc 
and as consequence of the fact that previous trials did not include some of the 
core set items chosen in the consensus exercise [13], we launched a longitudinal 
observational cohort of patients with early dcSSc (< 5 years from 1st non-
Raynaud’s phenomenon sign or symptom) at 4 US Scleroderma Centers with 
funding from the NIH [14]. The observational cohort recruited 200 patients over a 
period of 1-year with dcSSc defined as skin thickening proximal, as well as distal, 
to the elbows or knees, with or without involvement of the face and neck. 
Exclusion criteria included life expectancy of less than 1 year and non-proficiency 
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of the English language. All 31 core items emerged from the consensus meeting 
were included to enable an assessment of their psychometric properties 
(feasibility, reliability, and validity [including sensitivity to change]). Feasibility was 
defined as completion of the core set measure by > 50% of participants at two 
time points, redundancy was defined as either a Spearman or Pearson 
correlation coefficient of at least 0.80, while sensitivity to change was calculated 
over the 1-year period. Appropriate patient and physician anchors and transition 
questions were included to assess psychometric properties of core items. For 
example, modified Likert scale (transition health question) was employed by 
physicians and patients at 1-year follow up to determine the change in overall 
condition during the past year on a scale from 1 (“much better”) to 5 (“much 
worse”). Responses of 1 or 2 were considered an overall improvement, ratings of 
4 or 5 were considered a decline in health, while a rating of 3 meant that there 
was no appreciable change in overall health. Effect size (ES) was calculated 
using the transition questions as anchors and Cohen’s “rule-of-thumb” for 
interpreting ES: values of 0.20-0.49 represent a small change, values between 
0.50-0.79 a medium change, and ≥0.80 a large change[15]. Core set items that 
were significant at p< 0.20 (for dichotomous measures) or had an effect size ≥ 
0.20 in the “Improved” group (with respect to either patient or physician 
assessments) were further assessed using the modified content validity index 
matrix [16]. Seven Steering Committee members scored each cell on an ordinal 
scale (1-4). Each cell was scored according to the following scale: a score of 4 
(highest score) was assigned when the cell refereed to a value or an attribute 
 8 
well established in the literature or through systematically obtained information; a 
score of 3 indicated a value or an attribute somewhat known and accepted, but 
may need minor alteration or modification; a score of 2 indicated that the rater 
was unable to assess the attribute without additional information or research; 
and, finally a score of 1 (lowest score) meant that the attribute should definitely 
not be used as a core variable. Expert could also assign “not applicable” if they 
were unfamiliar with an item or different aspects of feasibility, reliability, and 
validity for the item. Cells scored as 3 or 4 were considered to be supportive of 
an individual item. Based on results from psychometrics analysis and expert 
input, a modified nominal group exercise was conducted via webinar by EHG 
where consensus was defined a priori as ≥75% agreement on each cell of the 
matrix and overall inclusion/ exclusion of the item as a core set item.  
 
B. Development and rating of paper patient profiles. We then developed 
paper patient profiles using actual data from two cohorts in part due to missing 
data in the NIH cohort. The Canadian Scleroderma Research Group (CSRG) 
data was included for patients with dcSSc and disease duration of < 5 years and 
completeness of data at baseline and follow-up on 15 core variables (except 
“patient skin interference”) were selected. Since the core variable “patient skin 
interference last month” was not measured in the Canadian cohort, we imputed 
its values. Using the NIH cohort, we determined which of the other 15 core 
variables were useful predictors of patient “skin interference last month” by fitting 
a linear regression to the NIH cohort data with patient skin interference as 
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outcome and the remaining 15 core variables as covariates. We fitted the linear 
regression model to the baseline data and the follow-up data separately and 
imputed the data for “patient skin interference” in the Canadian cohort.  
Since patient interviews were not performed as part of the Delphi and NGT, 
literature was searched to assess the most prevalent/ bothersome issues faced 
by patients with SSc [17, 18]. Based on this, pain and fatigue (as assessed by 
SF-36 vitality scale) were included as part of the patient profiles. 
Fifty-four international scleroderma experts in clinical care and trial design were 
subsequently invited to participate in a web-based evaluation of 20 patient 
profiles each. The experts were randomized based on their location (North 
America (29) vs. Rest of the World (25)) and years of experience (>10 years 
[N=38] vs. ≤ 10 years of scleroderma experience [N=16]). For each patient 
profile, the rater was asked three questions: 1. Do you think the patient has 
improved, stabilized, or worsened (or unable to tell) over 1-year; 2. If the patient 
was rated improved or worsened, by how much: considerably, somewhat, or a 
little; and 3. Please rank the three most important variables that influenced your 
decision regarding change or stability. Here, the physician raters could choose all 
the core items from a pull-down menu. Consensus was called if a proportion of at 
least 75% among those who rated the same patient profile agreed that the 
patient was improved, stable or worsening. When there was lack of consensus, 
the Steering Committee members were asked to rate the profiles that were not 
assigned to them before, followed by a web-based nominal group exercise to 
discuss each profile in detail. These patient profile ratings were then included 
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with the previous voting and percentage consensus was recalculated. If the 
proportion of agreement on a patient profile was ≥ 75%, the patient was deemed 
as having reached consensus. Finally, we sought consensus among SSc experts 
on which level of change in internal organ involvement would deem a patient as 
not improved.  
To determine whether there was a clear distinction among the 16 core variables 
in their helpfulness to guide raters in determining whether a patient was improved 
or not, we conducted a cluster analysis. We used the responses from the raters 
to the question “Please rank the most important variables that influenced your 
decision regarding change or stability”, and we clustered the 16 core variables 
based on the number of times a variable was ranked the most useful, the second 
most useful and the third most useful. Specifically, we applied the K-means 
algorithm to the 16x3 data matrix appropriately normalized and rescaled. Since 
the K-means algorithm requests that the number of clusters in which to group the 
data be specified a priori, we determined the number of clusters by running the 
algorithm with K=1,2,..15 clusters. For each number of clusters K, we computed 
the within-clusters sum of squares, which provides an indication of the degree of 
similarity within clusters. A lower within-sum of squares is better as it indicates 
that the clusters are rather homogeneous within themselves but they are different 
from one another. To determine the number of clusters K, we evaluated for which 
K there was the largest drop in the within-cluster sum of squares compared to the 
previous value (corresponding to K-1 clusters), but after which (for K+1 clusters) 
there was not a considerable change.  
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Development of response definitions 
Using only profiles where consensus was reached, we fitted logistic regression 
models to the binary outcome representing whether a patient had been rated by 
experts as being improved (=1) vs. not (=0) and with change in the core items as 
covariates. For each model, we calculated sensitivity, specificity and area under 
the curve (AUC). Additionally, using the estimates of the logistic regression 
coefficients, we derived, for each patient profile, the predicted log-odds (and 
thus, the predicted probability) that the patient would be rated as improved. We 
then compared the predicted probability to the raters’ consensus opinion on the 
patient. Accuracy of the predictions could be evaluated in different ways. Using 
the predicted probabilities in their continuous form, accuracy in the predictions 
can be quantified via the Brier score [19], a scoring rule that can be interpreted 
as the equivalent of the Mean Squared Error of the predicted probabilities 
compared to the binary (yes-improved=1, no-not improved=0) truth.  
If yi represents the raters’ consensus opinion on patient i with yi =1 if the patient 
has been rated as improved and yi =0 if the patient has been rated as not 
improved, and pi is the predicted probability that the patient is improved, obtained 
from the logistic regression model, the Brier score is defined as: 
𝐵𝑟𝑖𝑒𝑟 𝑆𝑐𝑜𝑟𝑒 =
1
𝑁
∑(𝑝𝑖 − 𝑦𝑖)
2
𝑁
𝑖=1
 
The Brier score, ranges from 0 to 1, can be used for model selection with the 
model having the lowest Brier Score having the best predictive performance.  
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We also tested whether the distribution of the predicted probabilities have a 
different distribution for the patient profiles who were rated improved by the 
experts and for those who were rated not improved by performing the non-
parametric Mann-Whitney test. Alternatively, the predicted probabilities could be 
transformed into binary classifications by choosing a threshold and defining 
“improved” all the patients for which the predicted probability is above the chosen 
threshold and “not improved” all the patients for which the predicted probability is 
below the threshold. To identify which threshold (e.g. cut point) to use, we 
considered different possible cut points from 0.1 to 1.0. For each of the 
thresholds considered, we derived the corresponding sensitivity and specificity. 
We made a plot of the sensitivity and specificity as a function of the threshold 
and determined which threshold had the highest sensitivity and specificity. The 
data-driven definitions were discussed with the Steering Committee regarding 
content and face validity.  
To evaluate the contribution of each core component to the final CRISS index, 
we computed the generalized coefficient of determination R2 for logistic 
regression [20].  
Validation in an independent cohort 
The index was tested in a randomized controlled trial of methotrexate vs. placebo 
in early dcSSc [21]. This trial was chosen as individual patient data were and all 
final variables were available in this database. We applied the CRISS index to 
the subjects with complete data and, for each subject, derived the predicted 
probability that a subject was improved using the predicted probability equation 
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(see Results section). We transformed the continuous predicted probabilities 
ranging from 0 to 1 into a binary classification, by defining of each subject 
“improved” or “not improved” depending on whether the predicted probability was 
above 0.6 or not. We then tested whether the probability of being improved was 
independent of being on methotrexate (e.g. whether the probability of being 
improved was the same in the groups of subjects) by performing a chi-square 
test. We also assessed whether the distributions of the predicted probabilities for 
the subjects on methotrexate and subjects on placebo were different using the 
Mann-Whitney test.  
 
 
Results 
Structured Consensus Exercise 
Eleven domains and 31 items were identified as the core set meeting OMERACT 
filters. The 11 domains included: skin, musculoskeletal, cardiac, pulmonary, 
gastrointestinal, renal, Raynaud’s phenomenon, digital ulcers, health-related 
quality of life and function, global health, and biomarkers. OMERACT input was 
obtained during the consensus exercise [3, 22]. 
 
NIH observational registry 
Two hundred patients with early dcSSc were recruited at baseline and 150 had 
complete baseline and 1-year data. In these 150 patients, mean (SD) age was 
50.4 (11.7), years, 74.7% were female, 78% were Caucasian and 10.7 % were 
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Latino with mean disease duration (dated from 1st non-Raynaud’s sign or 
symptom) of 2.3 (1.5) years, mean modified Rodnan skin score (mRSS) of 21.4 
(10.1) units, mean FVC% predicted of 82.3% (18.5) and mean HAQ-DI of 1.0 
(0.8; Table 1). 
 
Measures that lacked feasibility due to low completion rate (<50%) at 1 year 
included durometer (a measure of skin hardness [23]), right heart catheterization, 
Borg dyspnea index, 6-minute walk test, and Raynaud’s Condition Score [24] that 
required patient diary records. 
 
Using patient global assessment anchor of improved vs. not, 57% were rated as 
‘improved’ and 43% were rated as “non-improved”.  Using physician global 
assessment anchor of improved vs. not, 58% were rated as ‘improved’ and 42% 
were rated as “non-improved”.  Using these anchors, 5 items were found to be 
not responsive to change or insufficiently common: tender joint count, presence 
of renal crisis, estimated GFR, body mass index, presence of digital ulcers, and 
ESR. EHG led a modified nominal group review wherein consensus was 
achieved on domains/ items that should be used for development of paper 
patients (Figure 2). It was decided to keep renal crisis and presence/absence of 
digital ulcers as core set items due to their impact of prognosis in early dcSSc. 
No redundancy was noted in the 16 core measures at baseline and changed 
scores as assessed by the correlation coefficients (Appendix Tables 1-2). 
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Patient Profiles 
Patient profiles (examples shown in the Appendix Tables 3-5) were rated by 40 
experts (74% completion). In response to the question, “Please rank the most 
important variables that influenced your decision regarding change or stability”, 
experts ranked MRSS as most important 44% of the time, followed by FVC% 
predicted (14.5%), patient global assessment (11.0%), physician global 
assessment (9.1%), and HAQ-DI (8.0%; Table 2). All other core measures were 
ranked as most influential in the decision making less than 2% of the time.  
Examination of the within-cluster sum of squares seem to indicate that K=2 is a 
good choice. We then clustered the 16x3 matrix using 2 clusters and obtained 
that MRSS, FVC% predicted, patient global assessment, physician global 
assessment, and HAQ-DI clustered together and were separated statistically 
from the remaining core variables (Table 2). 
 
Consensus was achieved in 107 (71.3%) of patient profiles. The Steering 
Committee reviewed and discussed those profiles on which consensus was not 
reached and rescored them as improved, worsened or stable (if not done 
previously by the individual) using nominal group techniques. Following this, final 
consensus was achieved in 118 (78.7%) profiles that were used for developing 
the response definitions.  
 
Logistic regression models 
 16 
Using data from the 118 profiles where consensus was reached, we fit logistic 
regression models with binary outcome whether a patient had been rated by 
experts as being improved vs. not and as covariates the change from baseline to 
follow-up in the 16 core variables. We examined various models, increasing at 
each step the number of predictors included in the logistic regression model. In 
1-variable models (models where only one covariate was included), AUC ranged 
from 0.47 (for change in presence/absence of new digital ulcers) to 0.92 (for 
change in MRSS; Appendix Table 6). In a 2-variable model, change in MRSS 
and change in FVC% predicted yielded the highest AUC (0.96; Appendix Table 
7) but was deemed not to have content validity. Different definitions of response 
and their corresponding AUC, sensitivity and specificity were discussed by the 
Steering Committee (data available from the corresponding author). The 5-
variable model including change in MRSS, FVC% predicted, physician global 
assessment, patient global assessment, and HAQ-DI was voted as having the 
greatest face validity (Table 3). This model had a sensitivity of 0.982 (95% CI 
0.982, 0.983), specificity of 0.931 (95% CI 0.930, 0.933), and AUC of 0.986. The 
Brier score was 0.038 (lower score has better predictive performance). As the 
data was non-normally distributed, non-parametric test indicated that the 
distributions of the predicted probability of improving were different for the 
subjects who improved and those who did not (p-value < 0.0001; Figure 1a). 
Using depiction of sensitivity vs. specificity of improved vs. not improved group, a 
threshold of 0.6 had the best combination of specificity and sensitivity values 
(Figure 1b).  
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Defining a patient who is non-improved irrespective of improvement in 
other core measures 
The Steering Committee considered circumstances where a patient may improve 
in a particular outcome measure (such as MRSS or FVC% predicted) but have 
clinically significant worsening or end organ damage to another organ (e.g., 
development of renal crisis or PAH). There was consensus that such patients 
should not be considered as improved in a clinical trial. The Steering Committee 
voted on new onset of renal crisis, new onset or worsening lung fibrosis, new 
onset PAH, or new onset of left ventricular failure (Table 4). The international 
experts subsequently endorsed these definitions as well. 
 
Application in trial 
CRISS is a 2-step process. In step 1, subjects who develop new onset of renal 
crisis, new onset or worsening lung fibrosis, new onset PAH, or new onset of left 
ventricular failure (Table 4) during the trial are considered as non-improved and 
assigned a probability of 0.0. For the remaining subjects with complete data, 
Step 2 involves assigning the predicted probability of improving for each subject 
using the following equation (equation to derive predicted probabilities from a 
logistic regression model): 
 
 
𝑒𝑥𝑝[−5.54 − 0.81 ∗ ∆𝑀𝑅𝑆𝑆 + 0.21 ∗ ∆𝐹𝑉𝐶% − 0.40 ∗ ∆𝑃𝑡−𝑔𝑙𝑜𝑏 − 0.44 ∗ ∆𝑀𝐷−𝑔𝑙𝑜𝑏 − 3.41 ∗ ∆𝐻𝐴𝑄−𝐷𝐼]
1 + 𝑒𝑥𝑝[−5.54 − 0.81 ∗ ∆𝑀𝑅𝑆𝑆 + 0.21 ∗ ∆𝐹𝑉𝐶% − 0.40 ∗ ∆𝑃𝑡−𝑔𝑙𝑜𝑏 − 0.44 ∗ ∆𝑀𝐷−𝑔𝑙𝑜𝑏 − 3.41 ∗ ∆𝐻𝐴𝑄−𝐷𝐼]
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where MRSS indicates the change in MRSS from baseline to follow-up, FVC  
denotes the change in FVC% predicted from baseline to follow-up, Pt-glob 
indicates the change in patient global assessment, MD-glob denotes the change in 
physician global assessment, and HAQ-DI  is the change in HAQ-DI. All changes 
are absolute change (Time2 –Timebaseline). Subjects for which the predicted 
probability is greater or equal to 0.60 are considered improved, while subjects for 
which the predicted probability is below 0.60 are considered non-improved. The 2 
groups (drug vs. placebo) can then be compared in a 2x2 table and using 
appropriate significance tests. The predicted probabilities obtained using the 
CRISS can also be assessed as a continuous variable and the distributions of 
the probability of improving for patients on drug vs. placebo can be compared 
using non-parametric tests. 
 
Contribution of 5 core components to the CRISS 
We computed the R2 for the logistic regression models that had each of the 5 
core components of the CRISS as the single predictors. MRSS explained 66.3% 
of the variation, FVC% predicted explained 36.1% of the variation, physician 
global assessment explained 24.5% of variation, patient global assessment 
explained 23.7% variation, and 28.5% was explained by HAQ-DI. 
 
To assess how changes in the core variables are related to the predicted 
probabilities of improving on each patient profile, Appendix Figure 1(a)-(e) 
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presents scatterplot of the change in MRSS, change in FVC% predicted, change 
in the patient global, change in physician global and change in HAQ-DI versus 
the predicted probabilities for the 118 patient profiles. A change in MRSS, FVC% 
predicted and HAQ-DI are strong indicators of whether a patient is likely to be 
improved or not. In each scenario, a decrease of MRSS or HAQ-DI from baseline 
to follow-up and an increase in FVC% predicted corresponds to very high 
probabilities of improving. For patient global and physician global, the association 
between probability of improving and change in these two core components is 
less evident. 
  
Validation in a clinical trial 
We used the individual patient data from the methotrexate vs. placebo trial to 
assess our definition of response. Data for change in MRSS, FVC% predicted, 
patient global assessment, physician global assessment, and HAQ-DI was 
available for 35 of 71 patients at 1 year. Using the CRISS, we derived the 
predicted probability of improving for each of the 35 patients and classified them 
into improved and not improved using a probability cutoff of 0.6. With this 
criterion, 11 of 19 subjects who were on methotrexate were rated as improved 
whereas 3 of 16 subjects in placebo were rated as improved (p=0.04; Appendix 
Figure 2). When the data was assessed as continuous measure, the distribution 
of the predicted probability for improvement were statistically different (p= 0.02). 
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Discussion 
 
We have developed a composite index for trials in early dcSSc using well-
established consensus and data-driven approaches. The index includes 
measures that assess change in two common and prominent manifestations of 
early dcSSc (skin and ILD), functional disability (as assessed by HAQ-DI), and 
patient and physician global assessments. In addition, the index captures 
clinically meaningful decline in internal organ involvement that deems the patient 
has not improved during the clinical trial.  We subsequently validated this in a 
clinical trial and showed that CRISS index can differentiate methotrexate from 
placebo in early dcSSc.  
Traditionally, trials in early dcSSc have focused on skin or lung involvement [25, 
26]. MRSS has been used as the primary outcome measure for the trials of skin 
fibrosis [5]. MRSS meets the OMERACT criteria as a fully validated measure of 
outcome [27], but is also a surrogate of internal organ involvement and mortality 
in early dcSSc [28, 29]. However, the trials to date have largely been negative 
and MRSS has been questioned as primary outcome measure where post-hoc 
analysis of negative trials has shown stability/ improvement in MRSS over time 
[30, 31]. The CRISS index is the first step is capturing the multisystem 
involvement of dcSSc and includes patient perspective and impact on functional 
disability.  
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The CRISS index is calculated as a 2-step process. The first step evaluates 
clinically significant decline in renal or cardiopulmonary involvement and if 
present, the patient is adjudicated as non-improved. The second step assesses 
remaining patients and calculates the predicted probability of improvement. Here, 
the Steering Committee discussed different response definitions and decided to 
go with a data-driven definition rather than using a percent improvement 
definition, that includes expert consensus, as suggested by the ACR 
subcommittee [32]. In addition, data-driven definitions (e.g., disease activity index 
for rheumatoid arthritis [33]) have been successfully used for regulatory approval 
in other rheumatic diseases.   
The goal of CRISS is assess new pharmacologic agents that target the 
underlying pathogenesis and have impact on overall disease activity/ severity. 
Our hope is that CRISS use in patients with dcSSc will greatly facilitate the 
interpretation of results from clinical trials and form the basis for drug approval. 
Rather than using numerous outcomes that vary from trial to trial, the core set of 
measures used in CRISS will produce a single efficacy measure. This process 
will lessen the ambiguity associated with the presentation of multiple test 
statistics, some of which may be significant and others not and facilitate meta-
analysis. It will likely also allow a decrease in the patients necessary for 
appropriately powered clinical trials, as it has been true for the use of combined 
indices in rheumatoid arthritis. It should also be noted that the use of CRISS 
does not preclude the addition of other measures in a trial; it simply provides one 
standardized outcome that can be easily compared and understood.  If the goal 
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of the trial is to focus on a particular organ (e.g., use of vasodilators for 
underlying digital ulcers), then CRISS index is can be used as a secondary/ 
exploratory measure. 
The initial panel of domains (11) and items (31) offered a comprehensive view of 
the marked heterogeneity of SSc and at first was seen to potentially mimic the 
comprehensive structure of BILAG and SLEDAI [34]. However, many items were 
discarded based on lack of sensitivity to change in our actual data gathering 
exercise and others were demonstrated to lack feasibility. It is the data-driven 
basis for our approach to development of the CRISS, which supports our 
relatively simple and accessible panel of items.  
 
Our research has many strengths. It is first concerted effort by the scleroderma 
community to address lack of a robust composite index for a multisystem 
disease. We used well-accepted expert consensus and data-driven 
methodologies and successful derived and validated the index in early dcSSc. 
Second, the index captures organ involvement in early dcSSc, patient 
assessment of their overall disease, functional disability, and physician global 
assessment.  
Our study is not without limitations. First, the CRISS index is developed for early 
dcSSc and may not be valid for late dcSSc or lcSSc. A similar exercise in late  
lcSSc might focus on vascular complications such as digital ulcers or pulmonary 
arterial hypertension but would not include MRSS. The majority of past and 
ongoing trials are focused on early dcSSc due to dynamic changes in skin and 
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internal organ involvement that may responsive to pharmacologic intervention. 
Second, we did not get patient input during development of the index. We 
acknowledged this limitation and searched the literature [17, 18] that led to 
inclusion of fatigue and pain during the development of patient profile but neither 
measure survived the nominal group exercises. Nonetheless; two of the 
constituent measures of the CRISS index include patient global assessment and 
patient-reported functional assessment.  
 
In conclusion, we have developed and provide initial validation of a novel 
composite index for clinical trials in early dcSSc.  
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Table 1: Baseline demographics of patients who participated in the NIH 
observational study with baseline and 1 year data 
 
 Baseline N  
Age, mean (SD) 150 50.4 (11.7) 
Female, N (%) 
 
 112 (75%) 
 
Race, N (%) 
Caucasian 
African American 
Asian 
150 117 (78%) 
13 (9%) 
11 (7%) 
Ethnicity, N (%) 
Hispanic 
Non-Hispanic 
150  
16 (11%) 
134 (89%) 
Disease duration (yrs), mean (SD) 144 1.59 (1.34) 
Years since first Raynaud symptom, mean 
(SD) 
128 2.87 (2.49) 
Years since first non-Raynaud symptom, mean 
(SD) 
129 2.32 (1.5) 
BMI, mean (SD) 96 26.02 (7.1) 
MRSS, mean (SD) 150 21.4 (10.1) 
Durometer, mean (SD) 113 272.4 (64.51) 
Forced vital capacity % predicted, mean (SD) 140 82.32 (18.50) 
Total lung capacity% predicted, mean (SD) 109 87.83 (20.38) 
Diffusion capacity of carbon monoxide % 
predicted, mean (SD) 
140 65.05 (20.86) 
HRCT consistent with ILD, N (%) 99 79 (80%) 
6-minute walking distance, mean (SD) 50 421.6 (139.25) 
Borg dyspnea (0-10 scale), mean (SD) 46 1.92 (1.51) 
Tendon Friction rubs, N (%) 140 40 (29) 
Small joint contractures, N (%) 133 78 (29) 
Large joint contractures, N (%) 133 39 (59) 
Digital tip ulcers, N (%) 150 15 (10%) 
HAQ-DI, mean (SD) 150 1.02 (0.79) 
Digital ulcers VAS (0-150), mean (SD) 134 20.93 (40.91) 
Raynaud’s VAS (0-150), mean (SD) 135 32.70 (40.81) 
Breathing VAS (0-150), mean (SD) 138 23.07 (36.72) 
GI VAS (0-150), mean (SD) 136 22.60 (34.44) 
Disease severity VAS (0-150), mean (SD) 138 56.40 (42.88) 
Pain VAS (0-10), mean (SD) 140 4.0 (2.8) 
SF-36 PCS, mean (SD) 138 37.56 (12.95) 
SF-36 MCS, mean (SD) 138 44.23 (6.00) 
Physician global assessment (0-10), mean 143 4.44 (2.19) 
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(SD) 
Patient global assessment 
(0-10), mean (SD) 
140 4.07 (4.0) 
Antinuclear antibody, N (%) 116 94 (81.0%) 
Anti-SCl-70 antibody, N (%) 115 34 (30%) 
Serum creatinine phosphokinase, mean (SD) 127 143.90 (184.5) 
Serum Platelets, mean (SD) 143 315.2 (102.5) 
Serum brain natriuretic peptide, mean (SD) 105 161.3 (824.0) 
Serum erythrocyte sedimentation rate, mean 
(SD) 
121 23.38 (22.64) 
Serum C-reactive protein, mean (SD) 116 2.08 (4.94) 
VAS=visual analog scale; PCS=Physical component scale; MCS=Mental 
component scale 
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Table 2. Ranking of the core variables by scleroderma experts and cluster 
analysis 
 
 
 
 
 
 
 
 
 
 
 
Variable Rank 1 (%)  Rank 2 (%) Rank 3 (%) Cluster 
MRSS 374 (44.1%) 131 (15.5%) 75 (8.9%) 1 
FVC% 
predicted 
123 (14.5%) 148 (17.5%) 72 (8.5%) 1 
Physician 
global 
assessment 
77 (9.1%) 116 (13.7%) 88 (10.4%) 1 
Patient global 
assessment 
93 (11%) 69 (8.2%) 115 (13.6%) 1 
HAQ-DI 68 (8%) 112 (13.2%) 99 (11.7%) 1 
Vitality SF-36 12 (1.4%) 37 (4.4%) 101 (11.9%) 2 
GI VAS 25 (2.9%) 44 (5.2%) 43 (5.1%) 2 
Pain  11 (1.3%)  38 (4.5%)  82 (9.7%)  2 
Tendon 
friction rubs 
11 (1.3%) 33 (3.9%) 23 (2.7%) 2 
Breathing 
VAS 
13 (1.5%)  25 (3%) 32 (3.8%) 2 
Digital ulcers 
VAS 
7 (0.8%) 38 (4.5%) 17 (2%) 2 
Raynaud’s 
VAS 
11 (1.3%) 18 (2.1%) 43 (5.1%) 2 
Patient 
interference 
skin last 
month 
2 (0.2%) 21 (2.5%) 22 (2.6%) 2 
No. digital 
ulcers 
9 (1.1%) 11 (1.3%) 17 (2%) 2 
Renal crisis 11 (1.3%) 3 (0.4%) 2 (0.2%) 2 
Body mass 
index 
1 (0.1%) 3 (0.4%) 15 (1.8%) 2 
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Table 3. Final CRISS model consisting of 5-variables with highest face validity  
 
Variables  
(calculated as 
change from 
baseline to 1 year) 
Area under 
the curve 
(AUC) 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Unadjusted 
Beta 
coefficients 
MRSS 
FVC predicted 
HAQ-DI 
Patient global 
assessment 
 Physician global 
assessment 
 
 
0.9935 
 
 
 
 
0.9464 
 
 
0.9310 
-1.06 
0.30 
-0.67 
-0.90 
 
-5.61 
 
Table 4 Expert consensus on definition of a patient who is not-improved during a 
trial 
 
Patient is considered not improved* if he/she develops 
– New scleroderma renal crisis 
– Decline in FVC% predicted≥ 15% (relative), confirmed by 
another FVC% within a month, HRCT to confirm ILD (if 
previous HRCT did not show ILD) and FVC% predicted below 
80% predicted** 
– New onset of left ventricular failure (defined as ejection 
fraction ≤45%) or new onset of pulmonary arterial 
hypertension requiring treatment** 
*Irrespective of improvement in other core items 
** Attributable to SSc 
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Figure 1: Expert consensus and data-driven approaches using to develop CRISS 
index.  
 
 
 
 
Delphi exercise and nominal group consensus meeting to select core 
items 
NIH-funded 1 year observational study 
Assess psychometric properties of core items using 2 cohorts and 
consensus meeting to select items for profiles 
Develop and rank paper patients by experts 
Develop candidate definitions for response and assess for 
performance   
Selecting top indices based on statistical performance and rank by 
experts using OMERACT attributes  
Test in prospective trial 
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Figure 2. (a) Distribution of the predicted probability of improving for patients rated improved by 
the experts (red curve) and patients rated not improved by experts (blue curve). (b) Sensitivity 
(red line) and specificity (blue line) of the predicted classification of patients into “improved” and 
“not improved” as a function of the predicted probability cutoff. The cutoff considered are 0.1, 0.2, 
0.3, … 0.9 and the predicted classification are derived as follow: if the predicted probability for a 
subject is greater than the probability cutoff, the subject is rated as “improved”, otherwise it is not.  
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Appendix Table 1. Correlation between the continuous variables among the 16 
core variables at baseline.  
 
 V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 
V1 1.0 -0.26 0.43 0.60 0.33 0.49 0.31 0.04 0.16 0.09 0.09 0.04 0.03 0.17 
V2  1.0 -0.22 -0.33 -0.23 -0.20 -0.18 0.02 -0.03 -0.17 -0.003 -0.11 -0.27 -0.16 
V3   1.0 0.46 0.57 0.66 0.56 0.23 0.26 0.17 0.02 -0.06 0.28 0.25 
V4    1.0 0.45 0.54 0.33 0.17 0.18 0.11 0.04 0.08 0.13 0.10 
V5     1.0 0.55 0.57 0.35 0.35 0.19 -0.02 0.01 0.41 0.30 
V6      1.0 0.60 0.19 0.44 0.26 0.11 0.06 0.30 0.22 
V7       1.0 0.17 0.47 0.41 0.11 0.09 0.34 0.33 
V8        1.0 0.15 0.06 -0.05 0.06 0.26 0.07 
V9         1.0 0.35 0.20 0.15 0.39 0.45 
V10          1.0 0.16 0.11 0.20 0.23 
V11           1.0 -0.04 -0.02 0.02 
V12            1.0 0.19 0.07 
V13             1.0 0.36 
V14              1.0 
 
V1=MRSS, V2=FVC predicted, V3=HAQ-DI, V4=MD global, V5=Patient global, V6=Patient skin 
interference, V7=Pain, V8=Vitality, V9=Raynaud VAS, V10=Digital Ulcers VAS, V11=Number of 
digital ulcers, V12=BMI, V13=Breathing VAS, V14=GI VAS  
*renal crisis and tendon friction rubs not included 
 
 
 
Appendix Table 2. Correlation between the change scores in the 16 core 
continuous variables.  
 
 
 V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 
V1 1.0 -0.30 0.22 0.26 0.16 0.32 0.21 0.12 0.17 0.17 -0.10 0.07 0.08 0.17 
V2  1.0 -0.39 -0.31 -0.27 -0.29 -0.33 0.03 -0.06 -0.17 0.10 0.002 -0.30 -0.10 
V3   1.0 0.17 0.27 0.31 0.23 -0.005 0.08 -0.05 -0.009 -0.18 0.30 0.05 
V4    1.0 0.25 0.46 0.19 -0.09 0.18 0.03 -0.08 0.04 0.33 0.26 
V5     1.0 0.13 0.25 -0.007 0.002 0.05 -0.14 -0.10 0.16 0.25 
V6      1.0 0.28 -0.08 0.15 -0.07 -0.02 0.22 0.30 0.02 
V7       1.0 0.07 0.27 0.10 0.22 0.11 0.33 0.23 
V8        1.0 0.001 -0.12 -0.03 0.01 -0.12 -0.14 
V9         1.0 0.20 0.35 0.20 0.23 0.47 
V10          1.0 -0.13 0.11 0.05 0.36 
V11           1.0 0.008 0.06 0.05 
V12            1.0 0.16 -0.07 
V13             1.0 0.28 
V14              1.0 
V1=MRSS, V2=FVC predicted, V3=HAQ-DI, V4=MD global, V5=Patient global, V6=Patient skin 
interference, V7=Pain, V8=Vitality, V9=Raynaud VAS, V10=Finger Ulcers VAS, V11=Number of 
digital ulcers, V12=BMI, V13=Breathing VAS, V14=GI VAS  
*renal crisis and tendon friction rubs not included 
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Appendix Table 3. Example of a patient rated as “improved” by the experts. 
Predicted probability of improving is 0.99 according to CRISS index. 
 
 Baseline Follow-up Absolute  
change 
 
Age 
 
51.6 yrs 
 
Disease duration 
(months) 
 
12.98 
 
Global 
assessments 
   
Patient global 
assessment (0-10) 
3 1 -2 
MD global 
assessment (0-10) 
3 3 0 
Muscoloskeletal    
HAQ-DI (0-3) 0.625 0 -0.625 
Tendon friction rubs No No No change 
Skin    
MRSS (0-51) 13 3 -10 
Patient interference 
skin last month 
2 0 -2 
Lung    
FVC% predicted 62 75 13 
Breathing VAS  
(0-10) 
2 0 -2 
Renal    
Renal crisis No No No change 
Gastrointestinal    
GI VAS (0-10) 3 3 0 
Body Mass Index 
(BMI) 
25.40 26.58 1.18 
Raynaud’s    
Raynaud’s VAS (0-
10) 
2 1 -1 
Digital ulcers    
Digital ulcers VAS 
(0-10) 
0 0 0 
Number of digital 
ulcers 
0 0 0 
HRQOL    
Pain VAS (0-10) 3 1 -2 
Fatigue (SF-36 
Vitality scale) (0-
100) 
42.31 35.12 -7.19 
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Appendix Table 4. Example of a patient rated improved by the experts. Predicted 
probability of improving is 0.596 according to CRISS index. 
 
 Baseline Follow-up Absolute  
change 
 
Age 
 
64.65 yrs 
 
Disease duration 
(months) 
 
30.74 
 
Global 
assessments 
   
Patient global 
assessment (0-10) 
1 0 -1 
MD global 
assessment (0-10) 
7 4 -3 
Muscoloskeletal    
HAQ-DI (0-3) 0.375 0.250 -0.125 
Tendon friction rubs No No No change 
Skin    
MRSS (0-51) 21 15 -6 
Patient interference 
skin last month 
8 5 -3 
Lung    
FVC% predicted 86 81 -5 
Breathing VAS  
(0-10) 
0 0 0 
Renal    
Renal crisis Yes Yes No change 
Gastrointestinal    
GI VAS (0-10) 0 0 0 
Body Mass Index 
(BMI) 
25.12 24.82 -0.3 
Raynaud’s    
Raynaud’s VAS (0-
10) 
3 4 1 
Digital ulcers    
Digital ulcers VAS 
(0-10) 
0 8 8 
Number of digital 
ulcers 
0 0 0 
HRQOL    
Pain VAS (0-10) 0 2 2 
Fatigue (SF-36 
Vitality scale) (0-
100) 
35.12 35.12 0.0 
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Appendix Table 5. Example of a patient rated “worsened by the experts”. 
Predicted probability of improving is 0.002 according to the CRISS index. 
 
 Baseline Follow-up Absolute  
Change 
 
Age at baseline 
 
53.6 yrs 
 
Disease duration at 
baseline (months) 
 
43.3 
 
Global 
assessments 
   
Patient global 
assessment (0-10) 
1 2 1 
MD global 
assessment (0-10) 
1 2 1 
Muscoloskeletal    
HAQ-DI (0-3) 0 0 0 
Tendon friction rubs No Yes Change to worsen 
Skin    
MRSS (0-51) 7 5 -2 
Patient interference 
skin last month 
3 2 -1 
Lung    
FVC% predicted 87 80 -7 
Breathing VAS  
(0-10) 
0 1 1 
Renal    
Renal crisis No No No change 
Gastrointestinal    
GI VAS (0-10) 0 1 1 
Body Mass Index 
(BMI) 
24.68 24.68 0 
Raynaud’s    
Raynaud’s VAS (0-
10) 
0 3 3 
Digital ulcers    
Digital ulcers VAS 
(0-10) 
0 0 0 
Number of digital 
ulcers 
0 0 0 
HRQOL    
Pain VAS (0-10) 1 1 0 
Fatigue (SF-36 
Vitality scale) (0-
100) 
37.52 35.10 -2.42 
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Appendix Table 6. One variable logistic model using expert consensus definition 
of improved vs. not 
 
 
Variable 
Area under 
the curve 
(AUC) 
 
Sensitivity 
 
Specificity 
 
Brier  
Score 
MRSS 0.9231 0.8392 0.8793 0.108 
FVC predicted 0.7906 0.6429 0.7586 0.184 
MD global 0.7743 0.7143 0.7241 0.197 
Patient global 0.7448 0.7143 0.6207 0.204 
HAQ-DI 0.7107 0.6429 0.6897 0.200 
Pain 0.6857 0.6071 0.7586 0.218 
Vitality 0.6856 0.4643 0.7414 0.225 
VAS Breathing 0.6670 0.375 0.8103 0.219 
GI VAS 0.6667 0.7857 0.4483 0.220 
Patient 
interference 
skin 
0.6601 0.5179 0.7586 0.226 
Raynaud’s VAS 0.6190 0.4286 0.7241 0.238 
Tendon friction 
rubs 
0.5640 0.2321 0.8966 0.245 
Digital ulcers 
VAS 
0.5503 0.2857 0.7931 0.247 
BMI 0.4946 0.1786 0.8276 0.250 
Number of 
digital ulcers 
0.4764 0.0179 0.931 0.249 
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Appendix Table 7. Two variable logistic model using expert consensus definition 
of improved vs. not 
 
 
Variable 
Area under 
the curve 
(AUC) 
 
Sensitivity 
 
Specificity 
 
Brier 
Score 
MRSS, FVC 
predicted 
0.9632 0.8929 0.9138 0.068 
MRSS, HAQ-DI 0.9615 0.9107 0.8793 0.076 
MRSS, Patient 
global 
0.9560 0.875 0.8966 0.081 
MRSS, MD 
global 
0.9450 0.875 0.9310 0.094 
FVC predicted,  
HAQ-DI 
0.8519 0.7679 0.8448 0.158 
FVC predicted,  
Patient global 
0.8548 0.7679 0.8448 0.152 
FVC predicted,  
physician global 
0.8544 0.750 0.8103 0.158 
HAQ-DI,  
Patient global 
0.7982 0.7143 0.7241 0.184 
HAQ-DI,  
physician global 
0.8094 0.6607 0.7931 0.181 
Patient global,  
physician global 
0.8265 0.7321 0.7759 0.170 
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